二甲双胍与外周动脉疾病血运重建后生存改善和心脏事件减少相关,但对通畅率和保肢无影响
该回顾性研究纳入2001年6月至2014年12月因慢性肢体缺血(Rutherford 3-6级)行血运重建的患者,比较二甲双胍、其他降糖药、胰岛素及非糖尿病患者。二甲双胍组60个月生存率(60%)和无主要不良心脏事件率(44%)优于其他降糖药组和胰岛素组,但通畅率和保肢率与其他降糖药组及非糖尿病组无显著差异。
要点
- 二甲双胍组60个月生存率60%,优于其他降糖药组41%和胰岛素组30%(P<0.001)。
- 二甲双胍组60个月无主要不良心脏事件率44%,优于其他降糖药组37%和胰岛素组25%(P<0.001)。
- 二甲双胍组60个月保肢率84%、无主要不良肢体事件率71%,与其他降糖药组和非糖尿病组无显著差异。
核心结论
- 二甲双胍与外周动脉疾病患者生存改善和不良心脏事件减少相关,但对开放和腔内血运重建后的通畅率或保肢率无影响。
- 以胰岛素为主要治疗的糖尿病患者保肢率更差。
研究设计与样本
- 回顾性识别2001年6月至2014年12月因慢性肢体缺血(Rutherford 3-6级)行血运重建的患者。
- 采用Kaplan-Meier和Cox回归比较主要通畅率、次要通畅率、保肢率、主要不良肢体事件、主要不良心脏事件和生存率。
主要发现
- 非糖尿病组冠心病发生率46%,低于胰岛素组65%、二甲双胍组56%和其他降糖药组63%(P<0.001)。
- 胰岛素组终末期肾病发生率17%,高于非糖尿病组3%、二甲双胍组1.4%和其他降糖药组8%(P<0.001)。
- 二甲双胍组阿司匹林使用率94%,高于非糖尿病组86%、其他降糖药组83%和胰岛素组86%(P=0.02);他汀使用率71%,高于其他降糖药组64%、胰岛素组61%和非糖尿病组55%(P=0.002)。
- 胰岛素组严重肢体缺血比例93%,高于二甲双胍组59%、其他降糖药组72%和非糖尿病组50%(P<0.001)。
- 60个月主要通畅率非糖尿病组62%显著更优(P=0.005),二甲双胍组56%、其他降糖药组60%和胰岛素组51%之间无显著差异(P=0.06);60个月次要通畅率二甲双胍组76%、其他降糖药组85%、胰岛素组76%和非糖尿病组80%相似(P=0.27)。
关键数值与推荐
- 60个月保肢率胰岛素组62%显著更差(P<0.001),二甲双胍组84%、其他降糖药组83%和非糖尿病组87%之间无显著差异(P=0.45)。
- 60个月无主要不良肢体事件率胰岛素组53%,显著低于二甲双胍组71%、其他降糖药组70%和非糖尿病组67%(P=0.001)。
- 60个月生存率二甲双胍组60%和非糖尿病组60%显著优于其他降糖药组41%和胰岛素组30%(P<0.001)。
- 60个月无主要不良心脏事件率二甲双胍组44%和非糖尿病组52%显著高于其他降糖药组37%和胰岛素组25%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cardiovascular and limb-specific adverse outcomes is higher in peripheral arterial disease (PAD) patients with diabetes. Metformin is associated with improved cardiovascular morbidity and mortality. However, the effect of metformin on limb-specific outcomes is unclear. The objective of this study was to assess the effect of metformin on outcomes after intervention for PAD. METHODS: Patients who underwent revascularization for chronic limb ischemia (Rutherford 3-6) between June 2001 and December 2014 were retrospectively identified. Primary patency (PP), secondary patency (SP), limb salvage (LS), major adverse limb events (MALE), major adverse cardiac events (MACE), and survival rates were compared using Kaplan-Meier and Cox regression. RESULTS: One thousand sixty-four limbs in 1204 patients were identified (147 metformin, 196 other hypoglycemics [OH], 216 insulin, and 645 nondiabetics (nondiabetes mellitus [DM]). Non-DM had significantly lower incidence of CAD (46%) than insulin (65%), metformin (56%), and OH groups (63%) (P < 0.001). Insulin patients (17%) had significantly higher incidence of end-stage renal disease (ESRD) than non-DM (3%), metformin (1.4%), and OH groups (8%) (P < 0.001). Ninety four percent of patients in the metformin group were on aspirin, which was significantly higher than non-DM (86%), OH (83%), and insulin groups (86%) (P = 0.02). Similarly, statin use was significantly higher in the metformin group (71%) than in OH (64%), insulin (61%), and non-DM groups (55%) (P = 0.002). Majority of patients in the insulin group presented with critical limb ischemia (CLI) (93%), which was significantly greater than the metformin (59%), OH (72%), and non-DM groups (50%) (P < 0.001). Sixty-month PP was significantly greater in non-DM group (62%) (P = 0.005) in overall comparison with no significant difference between metformin (56%), OH (60%), and insulin (51%) groups (P = 0.06). Sixty-month SP was similar in metformin (76%), OH (85%), insulin (76%), and non-DM (80%) groups (P = 0.27). LS was significantly worse in insulin group (62%) (P < 0.001) with no significant difference between metformin (84%), OH (83%), and non-DM (87%) groups (P = 0.45). Freedom from MALE at 60 months was 53% in the insulin group, which was significantly worse as compared with metformin (71%), OH (70%), and non-DM (67%) groups (P = 0.001). Sixty-month survival was significantly improved in metformin (60%) and non-DM (60%) groups as compared with that in OH (41%) and insulin groups (30%) (P < 0.001). Freedom from MACE was significantly greater in metformin (44%) and non-DM (52%) groups than that in OH (37%) and insulin groups (25%) (P < 0.001). Metformin use (HR, 0.7 [0.5-0.9]; P = 0.008) was an independent factor associated with freedom from mortality. CONCLUSIONS: Metformin is associated with improved survival and decreased incidence of adverse cardiac events in PAD patients. However, it did not have an impact on patency or LS rates after open and endovascular interventions. LS was worse in diabetic patients primarily treated with insulin.
引用
- Khan SZ, Rivero M, Nader ND, et al. Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. Ann Vasc Surg. 2018. PMID: 30081159. doi:10.1016/j.avsg.2018.05.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。